# Suvorexant for Opioid/Stimulant Co-use

> **NCT05546515** · PHASE2 · COMPLETED · sponsor: **Johns Hopkins University** · enrollment: 20 (actual)

## Conditions studied

- Opioid Use Disorder
- Stimulant Use Disorder

## Interventions

- **DRUG:** Suvorexant (dual orexin receptor antagonist)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05546515
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-01
- **Primary completion:** 2024-11-30
- **Final completion:** 2024-11-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05546515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05546515, "Suvorexant for Opioid/Stimulant Co-use". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05546515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*